Literature DB >> 7545358

Role of prophylactic gastroenterostomy for unresectable pancreatic carcinoma.

S Egrari1, T X O'Connell.   

Abstract

Methods of palliation and the use of prophylactic gastroenterostomy in the treatment of unresectable pancreatic carcinoma remain controversial. Gastroenterostomy has been linked with various complications. We conducted a 10-year (1982-1992) retrospective review of patients who had unresectable pancreatic carcinoma and underwent biliary decompression without prophylactic gastroenterostomy. 50 patients were studied. Only four patients (8%) developed duodenal obstruction and required reoperation for therapeutic gastroenterostomy. The mean time to obstruction was 15.75 months, whereas the mean overall survival was 12.99 months. The mean survival of patients who underwent therapeutic gastroenterostomy was 32.25 months, with an average palliation of 16.5 months after the second operation. We conclude that pancreatic carcinoma has a rapid natural progression, and most patients do not survive long enough to obstruct. The ones who do obstruct are unique in that they survive for a long period of time. We recommend that routine prophylactic gastroenterostomy is unnecessary, and selective use of gastroenterostomy should be exercised in case of present or impending duodenal obstruction.

Entities:  

Mesh:

Year:  1995        PMID: 7545358

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  7 in total

1.  Hematemesis as the initial complication of pancreatic adenocarcinoma directly invading the duodenum: a case report.

Authors:  Yueh-Hung Lin; Chih-Yen Chen; Chih-Ping Chen; Tien-Yin Kuo; Full-Young Chang; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.

Authors:  K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

3.  Stomach-interposed cholecystogastrojejunostomy: a palliative approach for periampullary carcinoma.

Authors:  Chun-Yi Hao; Xiang-Qian Su; Jia-Fu Ji; Xin-Fu Huang; Bao-Cai Xing
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

4.  Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management.

Authors:  Ashish Shah; Abbas Fehmi; Thomas J Savides
Journal:  Dig Dis Sci       Date:  2014-04-30       Impact factor: 3.199

5.  Risk factors for morbidity and mortality following gastroenterostomy.

Authors:  Martin Poulsen; Mauro Trezza; Ghayyath H Atimash; Lars T Sorensen; Finn Kallehave; Ulla Hemmingsen; Lars N Jorgensen
Journal:  J Gastrointest Surg       Date:  2009-04-28       Impact factor: 3.452

6.  The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life.

Authors:  N Tjarda Van Heek; Steve M M De Castro; Casper H van Eijck; Rutger C I van Geenen; Eric J Hesselink; Paul J Breslau; T C Khe Tran; Geert Kazemier; Mechteld R M Visser; Olivier R C Busch; Hugo Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

7.  Palliative interventional and surgical therapy for unresectable pancreatic cancer.

Authors:  Volker Assfalg; Norbert Hüser; Christoph Michalski; Sonja Gillen; Jorg Kleeff; Helmut Friess
Journal:  Cancers (Basel)       Date:  2011-02-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.